1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Xintela AB (publ)

Xintela AB (publ)

XINT.ST
Xintela AB (publ)SE flagStockholm Stock Exchange
0.21
SEK
+0.00
- -
134.42MMarket Cap
Xintela AB (publ)
XINT.ST
(Stockholm Stock Exchange)

Recent

price

0.21

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
0.01
0.03
- -
- -
0.03
- -
- -
- -
- -
- -
0.01
- -
- -
Revenue per Share
-0.08
-0.24
-0.39
-0.43
-0.44
-0.45
-0.61
-0.61
-0.42
-0.37
-0.13
-0.07
-0.07
-0.07
Basic EPS, GAAP
-0.1
-0.26
-0.32
-0.41
-0.29
-0.54
-0.43
-0.26
-0.3
-0.4
-0.13
-0.07
-0.06
-0.06
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.09
-0.34
-0.76
-0.97
-1.27
-1.53
-1.83
-2.18
-1.7
-1.66
-0.82
-0.67
-0.62
-0.58
Book Value per Share
0.03
0.02
0.12
0.41
0.27
0.73
0.11
0.32
0.01
0.03
0.01
-0.01
-0.01
-0.02
Tangible Book Value per Share
30
33
30
42
50
58
72
83
141
181
422
573
690
750
Basic Weighted Avg Shares
- -
- -
1
- -
- -
2
- -
- -
- -
- -
- -
4
2
3
Sales/Revenue/Turnover
- -
-2,085.25
-1,521
-569,900
-1,096,650
-1,486.73
-100,121.05
- -
- -
- -
-73,380.77
-935.87
-2,045.75
-1,848.94
Operating Margin (%)
- -
- -
- -
1
1
2
4
4
3
4
4
1
1
1
Depreciation Expense
-2
-8
-12
-18
-22
-26
-44
-50
-60
-66
-54
-39
-49
-50
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-2,089.28
-1,526.95
-602,000
-1,097,250
-1,613.88
-114,552.63
- -
- -
- -
-69,337.18
-929.77
-2,128.13
-1,931.03
Profit Margin (%)
1
- -
3
17
13
29
-5
17
-7
1
3
-7
-6
-18
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
5
4
7
21
18
45
9
28
3
6
4
-6
-5
-18
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
20
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
703
861
861
Market Capitalization
256
199
190

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
9
29
14
Cash, Cash Equivalents & STI
3
23
10
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
37
34
32
Payables & Accruals
- -
- -
- -
ST Debt
- -
20
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
19.81%
-46.36%
-11.38%
Free Cash Flow
27.34%
24.61%
2.25%
Net Income, GAAP
18.64%
1.55%
23.92%
Sales/Revenue/Turnover
- -
- -
-45.86%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
3
1
4
2025
- -
1
1
- -
2
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.02
-0.02
-0.01
-0.02
-0.07
2025
-0.02
-0.02
-0.01
-0.02
-0.07
2026
-0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Advagene Biopharma Co., Ltd. (6709.TWO)
Silence Therapeutics plc (SLNCF)
Enimmune corporation (6564.TWO)
Alpine Immune Sciences, Inc. (ALPN)
Kazia Therapeutics Limited (KZA.AX)
Cellectis S.A. (CMVLF)
Business
Xintela AB (publ) is a biopharmaceutical firm engaged in the advanced fields of regenerative medicine and targeted oncology, concentrating on significant medical needs such as cartilage repair and aggressive tumor treatments. The company's innovative work is founded on its patented integrin α10β1 marker technology, which precisely identifies and isolates specific stem cells for therapeutic applications and targets particular cancer cells. Its flagship human stem cell product, XSTEM, is undergoing clinical evaluation for the management of knee osteoarthritis, where recent 24-month findings have demonstrated sustained safety, reduced discomfort, enhanced joint functionality, and improved cartilage and bone structure, indicating a disease-modifying capability. XSTEM is also in clinical trials for chronic, slow-healing leg ulcers, with the final patient recently treated to assess both safety and wound repair. Furthermore, Xintela is progressing XSTEM through preclinical stages for Acute Respiratory Distress Syndrome. For animal health, EQSTEM, a stem cell product targeting equine joint ailments, has been developed and is now globally licensed to EQGen Biomedical. Through its fully owned subsidiary, Targinta AB, the company is also pioneering first-in-class therapeutic antibodies, TARG9 and TARG10, that target integrin α10β1 for severe cancers, including triple-negative breast cancer, glioblastoma, and aggressive sarcoma, with a recent partnership established with Memorial Sloan Kettering Cancer Center for sarcoma antibody development. Xintela AB (publ) was established in 2009 and operates from Lund, Sweden.